Roivant Sciences gained U.S. FDA approval for LISRAYA to treat adults with dermatomyositis, with a wholesale Acquisition cost of $35,000 for a 30-count bottle of 30 mg tablets. Investors now have a disclosed regulatory milestone and a stated wholesale price for the treatment.
Key Highlights
- Roivant posted an investor presentation on August 28, 2026.
- The presentation identifies LISRAYA’s generic name as brepocitinib.
- Roivant Sciences Ltd. gained U.S. Food and Drug Administration approval for LISRAYA.
- LISRAYA is approved to treat adults with dermatomyositis.
FDA Approval
Roivant Sciences Ltd. gained U.S. Food and Drug Administration approval for LISRAYA, marking the regulatory approval described in the article. The approval covers treatment of adults with dermatomyositis, establishing the specific patient population identified in the announcement.
The article presents the approval as the central development for Roivant Sciences. It does not describe additional approved uses, broader patient populations or other regulatory decisions beyond LISRAYA’s use in adults with dermatomyositis.
Product Identity
LISRAYA is the Brand name for brepocitinib, according to the presentation referenced in the article. This identifies the product by both its commercial name and the name associated with the treatment.
The naming information connects the approved product with brepocitinib without adding details about formulation, dosage, administration or treatment duration.
Approved Patient Population
The approved patient population consists of adults with dermatomyositis. This wording defines the group covered by the FDA approval described in the article and distinguishes the approval from any use outside that stated population. Accordingly, the available details support only the conclusion that the approval applies to adults with dermatomyositis.
Wholesale Acquisition Cost
LISRAYA’s wholesale acquisition cost is $35,000. The article presents this amount alongside the FDA approval and identifies it as the product’s wholesale acquisition cost.
No additional pricing framework, discount information, reimbursement terms or patient-access details are provided. The stated amount should therefore be understood as the pricing detail specifically supplied in the article, rather than as a broader description of actual transaction prices.
Forward-Looking Statements
The presentation contains forward-looking statements covering future operating results, financial position and Business strategy. It also addresses cash use, Capital allocation, Research and Development plans, Clinical Trials and potential commercial use of products following regulatory approval.
These statements concern possible future activities and outcomes rather than only completed events.
Risks and Uncertainties
The presentation cautions that actual results could differ materially from forward-looking statements. It attributes that possibility to risks and uncertainties, without listing particular risks in the article.
This caution applies to the areas covered by the forward-looking discussion, including operations, finances, strategy, capital decisions, development plans, trials and potential commercial use. The approval and stated wholesale acquisition cost are the concrete details provided, while future outcomes remain subject to the stated uncertainties.
Peers Moving on This News
- Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) up 2.0%
- Biodexa Pharmaceuticals plc (NASDAQ: BDRX) down 3.1%
- Immunocore Holdings plc (NASDAQ: IMCR) little changed




Please wait processing your request...